Applying Eligibility and Mutual Exclusivity Rules

After an MEA's potential value is scored, the system refines the list by applying strict rules to ensure only viable options remain. By the end of this lesson, you'll be able to evaluate how hard incompatibility and mutual exclusivity rules refine the list of eligible MEAs.

Core idea

Not every MEA is suitable for every asset, and some MEAs simply cannot exist together in the same agreement. The MEA selection tool uses hard incompatibility rules to remove MEAs that are fundamentally unsuitable for a given asset profile. These rules act as a filter, ensuring that only logically coherent options proceed. For example, a "one-off" treatment cannot use an MEA that requires repeated transactions over time, like a subscription.

Beyond basic incompatibility, mutual exclusivity rules address situations where certain MEAs cannot be combined within a single agreement. While the tool ranks all MEAs independently as potential standalone options, it flags those that have internal compatibility constraints. The most restrictive is a Subscription MEA, which by its nature covers all payment terms and therefore cannot be combined with any other financial mechanism in the same contract. Other examples include combining population-level and patient-level caps, as these track volume at different levels and would lead to double-counting within one agreement.

Walkthrough

Let's consider an example where the tool applies these rules.

Task: Imagine you are evaluating a new one-off treatment for a single indication with strong evidence and a homogeneous patient population.

1. Identify Hard Incompatibility Rules:

   • One-off treatment: This immediately triggers several exclusions. MEAs like Subscription, Population volume cap, Patient volume cap, Population cost cap, and Patient price-volume are all removed because they require repeated transactions over time.
   • Single indication: This excludes Indication-based pricing, as this mechanism requires multiple indications or distinct subgroups to be viable.
   • Strong evidence AND Homogeneous population: This combination removes Coverage with evidence development and Restricted/conditional coverage because there's no evidence gap or population uncertainty to address.
   • If we also had "Active comparator" in the profile, Outcome-guarantee would be excluded due to the lack of clinical uncertainty to underwrite.

2. Consider Mutual Exclusivity Rules:

   • After the hard incompatibility rules have filtered the list, the remaining MEAs are ranked. If Subscription were still present (which it isn't in this example due to the "one-off" treatment type), the tool would display a note indicating it "Must always be a standalone agreement — incompatible with all other mechanisms."
   • Similarly, if both Population volume cap and Patient volume cap were eligible and highly ranked, the tool would flag that they "Cannot be combined in the same agreement."

By applying these rules, the tool ensures that the final list of recommended MEAs is not only well-scored but also practically viable and logically consistent with the asset's characteristics.

Common mistakes

• Confusing hard incompatibility with mutual exclusivity: Hard incompatibility removes an MEA entirely from consideration for a given asset. Mutual exclusivity flags that within a single agreement, certain MEAs cannot coexist, but they might still be viable as standalone options.
• Overlooking the rationale: Each rule has a clear reason (e.g., "requires repeated transactions," "no evidence gap"). Understanding the 'why' helps you anticipate which MEAs will be excluded.

Key takeaways

• Hard incompatibility rules remove MEAs that are fundamentally unsuitable for an asset's characteristics (e.g., one-off treatment cannot use a subscription model).
• These rules act as a strict filter, ensuring only logically viable MEAs proceed to scoring and ranking.
• Mutual exclusivity rules identify MEAs that cannot be combined within the same agreement (e.g., population-level and patient-level caps).
• The tool flags mutually exclusive MEAs with a "single-agreement note" rather than removing them, as they can still be valid standalone options.
• Understanding these rules helps refine the list of eligible MEAs, ensuring practical and coherent recommendations.